SK87993A3 - Pharmaceutical composition - Google Patents

Pharmaceutical composition Download PDF

Info

Publication number: SK87993A3
Authority: SK; Slovakia
Prior art keywords: group; pharmaceutical composition; composition according; formula; quinone
Prior art date: 1991-02-13

Application number

SK879-93A

Other languages

English (en)

Slovak (sk)

Inventor

Washington O Ayuko

Original Assignee

Radopath Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-02-13

Filing date

1992-02-13

Publication date

1993-12-08

1992-02-13 Application filed by Radopath Ltd filed Critical Radopath Ltd

1993-12-08 Publication of SK87993A3 publication Critical patent/SK87993A3/sk

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims abstract description 48
239000000203 mixture Substances 0.000 claims abstract description 40
DGQLVPJVXFOQEV-NGOCYOHBSA-N carminic acid Chemical compound OC1=C2C(=O)C=3C(C)=C(C(O)=O)C(O)=CC=3C(=O)C2=C(O)C(O)=C1[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DGQLVPJVXFOQEV-NGOCYOHBSA-N 0.000 claims abstract description 20
229940114118 carminic acid Drugs 0.000 claims abstract description 20
235000012730 carminic acid Nutrition 0.000 claims abstract description 20
239000004106 carminic acid Substances 0.000 claims abstract description 20
206010028980 Neoplasm Diseases 0.000 claims abstract description 19
238000011282 treatment Methods 0.000 claims abstract description 18
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 15
201000011510 cancer Diseases 0.000 claims abstract description 14
150000001875 compounds Chemical class 0.000 claims abstract description 14
239000003085 diluting agent Substances 0.000 claims abstract description 10
201000010099 disease Diseases 0.000 claims abstract description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
230000009385 viral infection Effects 0.000 claims abstract description 8
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 7
239000007788 liquid Substances 0.000 claims abstract description 6
BDJXVNRFAQSMAA-UHFFFAOYSA-N quinhydrone Chemical compound OC1=CC=C(O)C=C1.O=C1C=CC(=O)C=C1 BDJXVNRFAQSMAA-UHFFFAOYSA-N 0.000 claims abstract description 6
DGQOCLATAPFASR-UHFFFAOYSA-N tetrahydroxy-1,4-benzoquinone Chemical compound OC1=C(O)C(=O)C(O)=C(O)C1=O DGQOCLATAPFASR-UHFFFAOYSA-N 0.000 claims abstract description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 5
229940052881 quinhydrone Drugs 0.000 claims abstract description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 3
150000004053 quinones Chemical class 0.000 claims description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
238000002560 therapeutic procedure Methods 0.000 claims description 8
208000036142 Viral infection Diseases 0.000 claims description 7
241001465754 Metazoa Species 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 6
PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 claims description 6
150000004056 anthraquinones Chemical group 0.000 claims description 6
125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
125000000962 organic group Chemical group 0.000 claims description 6
238000011321 prophylaxis Methods 0.000 claims description 6
208000030507 AIDS Diseases 0.000 claims description 4
239000008367 deionised water Substances 0.000 claims description 4
229910021641 deionized water Inorganic materials 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
229910052757 nitrogen Inorganic materials 0.000 claims description 4
235000019483 Peanut oil Nutrition 0.000 claims description 3
239000000312 peanut oil Substances 0.000 claims description 3
239000002202 Polyethylene glycol Substances 0.000 claims description 2
CXORMDKZEUMQHX-UHFFFAOYSA-N kermesic acid Chemical compound O=C1C2=C(O)C(O)=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C CXORMDKZEUMQHX-UHFFFAOYSA-N 0.000 claims description 2
229940057995 liquid paraffin Drugs 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
239000003921 oil Substances 0.000 claims description 2
235000019198 oils Nutrition 0.000 claims description 2
229920001223 polyethylene glycol Polymers 0.000 claims description 2
125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 2
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
125000004429 atom Chemical group 0.000 claims 2
AYFBGZAKIZLFMY-UHFFFAOYSA-N 3,4,5-trihydroxy-1h-quinolin-2-one Chemical compound N1C(=O)C(O)=C(O)C2=C1C=CC=C2O AYFBGZAKIZLFMY-UHFFFAOYSA-N 0.000 claims 1
208000031295 Animal disease Diseases 0.000 claims 1
JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 claims 1
125000005843 halogen group Chemical group 0.000 claims 1
125000006501 nitrophenyl group Chemical group 0.000 claims 1
125000001424 substituent group Chemical group 0.000 claims 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 4
239000001257 hydrogen Substances 0.000 abstract 3
229910006127 SO3X Inorganic materials 0.000 abstract 1
229930182482 anthraquinone glycoside Natural products 0.000 abstract 1
229940098421 anthraquinone glycoside Drugs 0.000 abstract 1
150000008139 anthraquinone glycosides Chemical class 0.000 abstract 1
150000003254 radicals Chemical class 0.000 description 11
210000004027 cell Anatomy 0.000 description 9
-1 hydroxy, amino Chemical group 0.000 description 9
230000000694 effects Effects 0.000 description 8
230000007246 mechanism Effects 0.000 description 8
238000000034 method Methods 0.000 description 7
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
230000037396 body weight Effects 0.000 description 5
238000009472 formulation Methods 0.000 description 5
210000001165 lymph node Anatomy 0.000 description 5
239000004480 active ingredient Substances 0.000 description 4
208000007502 anemia Diseases 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
210000000214 mouth Anatomy 0.000 description 4
210000000952 spleen Anatomy 0.000 description 4
206010061218 Inflammation Diseases 0.000 description 3
239000003963 antioxidant agent Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000002512 chemotherapy Methods 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
210000000265 leukocyte Anatomy 0.000 description 3
230000004044 response Effects 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
206010019842 Hepatomegaly Diseases 0.000 description 2
208000007514 Herpes zoster Diseases 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
RUQPQFLYDCXMGX-UHFFFAOYSA-N Spinochrome E Natural products OC1=C(O)C(O)=C2C(=O)C(O)=C(O)C(=O)C2=C1O RUQPQFLYDCXMGX-UHFFFAOYSA-N 0.000 description 2
206010041660 Splenomegaly Diseases 0.000 description 2
241000700605 Viruses Species 0.000 description 2
239000013543 active substance Substances 0.000 description 2
238000005804 alkylation reaction Methods 0.000 description 2
239000003048 aphrodisiac agent Substances 0.000 description 2
230000002509 aphrodisiac effect Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
238000004820 blood count Methods 0.000 description 2
230000036770 blood supply Effects 0.000 description 2
239000000969 carrier Substances 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
150000002367 halogens Chemical group 0.000 description 2
238000009169 immunotherapy Methods 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
238000007348 radical reaction Methods 0.000 description 2
238000007363 ring formation reaction Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
125000001894 2,4,6-trinitrophenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1[N+]([O-])=O)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
229930182476 C-glycoside Natural products 0.000 description 1
150000000700 C-glycosides Chemical class 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
241001415288 Coccidae Species 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
229940123457 Free radical scavenger Drugs 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
206010028116 Mucosal inflammation Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
229930192627 Naphthoquinone Natural products 0.000 description 1
206010054107 Nodule Diseases 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
238000009534 blood test Methods 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
208000019902 chronic diarrheal disease Diseases 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000001909 effect on DNA Effects 0.000 description 1
210000000256 facial nerve Anatomy 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000036449 good health Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
208000021039 metastatic melanoma Diseases 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
230000002969 morbid Effects 0.000 description 1
150000002791 naphthoquinones Chemical class 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
239000002516 radical scavenger Substances 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
238000011867 re-evaluation Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
206010040882 skin lesion Diseases 0.000 description 1
231100000444 skin lesion Toxicity 0.000 description 1
238000010186 staining Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
229910052723 transition metal Inorganic materials 0.000 description 1
150000003624 transition metals Chemical class 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B1/00—Dyes with anthracene nucleus not condensed with any other ring
- C09B1/02—Hydroxy-anthraquinones; Ethers or esters thereof
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B67/00—Influencing the physical, e.g. the dyeing or printing properties of dyestuffs without chemical reactions, e.g. by treating with solvents grinding or grinding assistants, coating of pigments or dyes; Process features in the making of dyestuff preparations; Dyestuff preparations of a special physical nature, e.g. tablets, films
- C09B67/0033—Blends of pigments; Mixtured crystals; Solid solutions
- C09B67/0034—Mixtures of two or more pigments or dyes of the same type
- C09B67/0038—Mixtures of anthraquinones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
AIDS & HIV (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Tropical Medicine & Parasitology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SK879-93A 1991-02-13 1992-02-13 Pharmaceutical composition SK87993A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB919103075A GB9103075D0 (en)	1991-02-13	1991-02-13	Trinitrobenzene derivatives and their therapeutic use
PCT/GB1992/000262 WO1992014454A1 (fr)	1991-02-13	1992-02-13	Utilisation de quinones dans le traitement du cancer ou du sida

Publications (1)

Publication Number	Publication Date
SK87993A3 true SK87993A3 (en)	1993-12-08

Family

ID=10689992

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK879-93A SK87993A3 (en)	1991-02-13	1992-02-13	Pharmaceutical composition

Country Status (30)

Country	Link
EP (1)	EP0499467A3 (fr)
JP (1)	JPH06505231A (fr)
CN (1)	CN1064407A (fr)
AP (1)	AP549A (fr)
AU (2)	AU1233992A (fr)
BG (1)	BG61025B1 (fr)
BR (1)	BR9205642A (fr)
CA (1)	CA2104009A1 (fr)
CZ (1)	CZ166893A3 (fr)
DZ (1)	DZ1559A1 (fr)
FI (1)	FI933595A7 (fr)
GB (2)	GB9103075D0 (fr)
GT (1)	GT199200009A (fr)
HU (1)	HUT65634A (fr)
IE (1)	IE920464A1 (fr)
IL (1)	IL100906A (fr)
IN (1)	IN178929B (fr)
IS (1)	IS3814A (fr)
JO (1)	JO1719B1 (fr)
LT (1)	LT3197B (fr)
MA (1)	MA22443A1 (fr)
MX (1)	MX9200622A (fr)
MY (1)	MY131098A (fr)
NO (1)	NO932681L (fr)
NZ (2)	NZ240487A (fr)
OA (2)	OA09535A (fr)
SK (1)	SK87993A3 (fr)
TN (1)	TNSN92015A1 (fr)
WO (1)	WO1992014454A1 (fr)
ZA (1)	ZA921037B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9103075D0 (en)	1991-02-13	1991-03-27	Washington Odur Ayuko	Trinitrobenzene derivatives and their therapeutic use
DZ1781A1 (fr) *	1993-05-21	2002-02-17	Radopah Ltd	Agents d'arylation.
EP0751768B1 (fr) *	1994-03-17	2000-12-27	Radopath Pharmaceuticals International Limited	Agent antiviral et anticancereux
ATE188870T1 (de) *	1994-10-04	2000-02-15	Lohmann Rudolf Lomapharm	Lösungen von anthrachinonen zur parenteralen applikation
US7482029B2 (en)	2005-04-01	2009-01-27	Bionovo, Inc.	Composition for treatment of menopause
US7537774B2 (en) *	2005-12-23	2009-05-26	Orion Therapeautics, Llc	Therapeutic formulation
WO2009021196A1 (fr)	2007-08-08	2009-02-12	Bionovo, Inc.	Extraits de ligustrum lucidum et leurs utilisations
AU2008296072A1 (en)	2007-09-07	2009-03-12	Bionovo, Inc.	Estrogenic extracts of Astragalus membranaceus Fisch.Bge.Var.mongolicus Bge. of the Leguminosae Family and uses thereof
AU2008296176A1 (en)	2007-09-07	2009-03-12	Bionovo, Inc.	Estrogenic extracts of Asparagus conchinchinensis (Lour.) Merr of the Liliaceae Family and uses thereof
EP2190292A4 (fr)	2007-09-07	2012-12-26	Bionovo Inc	Extraits oestrogéniques de scuttelaria barbata d. don de la famille labiatae et leurs utilisations
EP2060562A1 (fr) *	2007-11-16	2009-05-20	Laboratoire Medidom S.A.	Dérivés de sulfonate de dioxoanthracène
EP2219659A4 (fr)	2007-11-19	2010-11-17	Bionovo Inc	Procédés de détection et de traitement de cancers utilisant un extrait de scuttelaria barbata
EP2222323A4 (fr)	2007-11-19	2012-07-25	Bionovo Inc	Procédé de fabrication d'extrait purifié de la scutellaria barbata d.don
US20090312437A1 (en) *	2008-06-06	2009-12-17	Bionovo, Inc., A Delaware Corporation	Anthraquinones and Analogs from Rhuem palmatum for Treatment of Estrogen Receptor Beta-Mediated Conditions
WO2013055913A2 (fr)	2011-10-14	2013-04-18	Emory University	Inhibiteurs de pgam1 et procédés associés
CZ304335B6 (cs) *	2012-02-22	2014-03-12	Mikrobiologický ústav AV ČR, v. v. i.	Submerzní kmeny Quambalaria sp. CCM 8372 a CCM 8373, směs naftochinonových barviv jimi produkovaná, způsob jejich produkce a použití
WO2020016245A1 (fr) *	2018-07-17	2020-01-23	Pili	Dérivés anthraquinoniques et leur utilisation en tant qu'agents colorants

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE7708452L (sv) *	1977-07-22	1979-01-23	Allied Chem	Komposition innehallande en antrakinonforening
JPS6054286B2 (ja) *	1979-09-18	1985-11-29	江澤林	免疫増強剤
JPS6043210A (ja) *	1983-08-18	1985-03-07	Tdk Corp	磁気ヘツド及びその製造方法
DE3431236A1 (de) *	1984-08-24	1986-02-27	Carnivora-Deutschland GmbH, 7109 Jagsthausen	Verwendung von 1,4-naphthochinon-derivaten in niedrigen konzentrationen zur immunstimulation
DE3601065A1 (de) *	1986-01-16	1987-07-23	Behringwerke Ag	Chinon-derivate als antitumormittel
EP0348509B1 (fr) *	1987-12-10	1993-03-24	TSUMURA & CO.	Medicament antiretroviral
IE65715B1 (en) *	1988-08-16	1995-11-15	Wellcome Found	Medicaments
GB9103075D0 (en)	1991-02-13	1991-03-27	Washington Odur Ayuko	Trinitrobenzene derivatives and their therapeutic use
JPH06501449A (ja) *	1990-04-03	1994-02-17	ラドパス　リミテッド	癌またはウイル性疾患の治療におけるトリニトロベンゼン類またはカルミン酸の使用
DE4013023A1 (de) *	1990-04-24	1991-11-07	Lohmann Rudolf Lomapharm	Verwendung von anthrachinonderivaten zur prophylaxe und therapie von viruserkrankungen

1991
- 1991-02-13 GB GB919103075A patent/GB9103075D0/en active Pending
- 1991-11-05 NZ NZ240487A patent/NZ240487A/en unknown
1992
- 1992-02-10 IL IL10090692A patent/IL100906A/en not_active IP Right Cessation
- 1992-02-10 IN IN97DE1992 patent/IN178929B/en unknown
- 1992-02-11 NZ NZ241593A patent/NZ241593A/en unknown
- 1992-02-12 IS IS3814A patent/IS3814A/is unknown
- 1992-02-12 MA MA22730A patent/MA22443A1/fr unknown
- 1992-02-12 AP APAP/P/1992/000356A patent/AP549A/en active
- 1992-02-12 DZ DZ920016A patent/DZ1559A1/fr active
- 1992-02-13 BR BR9205642A patent/BR9205642A/pt not_active Application Discontinuation
- 1992-02-13 AU AU12339/92A patent/AU1233992A/en not_active Abandoned
- 1992-02-13 WO PCT/GB1992/000262 patent/WO1992014454A1/fr not_active Ceased
- 1992-02-13 CN CN92100817A patent/CN1064407A/zh active Pending
- 1992-02-13 OA OA60150A patent/OA09535A/en unknown
- 1992-02-13 MY MYPI92000228A patent/MY131098A/en unknown
- 1992-02-13 JO JO19921719A patent/JO1719B1/en active
- 1992-02-13 CZ CS931668A patent/CZ166893A3/cs unknown
- 1992-02-13 EP EP19920301185 patent/EP0499467A3/en not_active Withdrawn
- 1992-02-13 HU HU9302347A patent/HUT65634A/hu unknown
- 1992-02-13 JP JP4504180A patent/JPH06505231A/ja active Pending
- 1992-02-13 CA CA002104009A patent/CA2104009A1/fr not_active Abandoned
- 1992-02-13 TN TNTNSN92015A patent/TNSN92015A1/fr unknown
- 1992-02-13 ZA ZA921037A patent/ZA921037B/xx unknown
- 1992-02-13 IE IE046492A patent/IE920464A1/en unknown
- 1992-02-13 GB GB9203084A patent/GB2254554B/en not_active Expired - Fee Related
- 1992-02-13 MX MX9200622A patent/MX9200622A/es not_active Application Discontinuation
- 1992-02-13 SK SK879-93A patent/SK87993A3/sk unknown
- 1992-02-13 GT GT199200009A patent/GT199200009A/es unknown
1993
- 1993-02-05 LT LTIP329A patent/LT3197B/lt not_active IP Right Cessation
- 1993-07-26 NO NO93932681A patent/NO932681L/no unknown
- 1993-08-13 FI FI933595A patent/FI933595A7/fi not_active Application Discontinuation
- 1993-08-13 OA OA60399A patent/OA09810A/en unknown
- 1993-08-13 BG BG98041A patent/BG61025B1/bg unknown
1996
- 1996-06-11 AU AU55906/96A patent/AU5590696A/en not_active Abandoned

Also Published As

Publication number	Publication date
OA09810A (en)	1994-04-15
NZ240487A (en)	1994-03-25
FI933595A0 (fi)	1993-08-13
GT199200009A (es)	1993-08-06
IN178929B (fr)	1997-07-19
LT3197B (en)	1995-03-27
TNSN92015A1 (fr)	1993-06-08
GB2254554B (en)	1995-09-20
JO1719B1 (en)	1992-12-15
NZ241593A (en)	1995-05-26
NO932681D0 (no)	1993-07-26
BG61025B1 (bg)	1996-09-30
BG98041A (bg)	1994-05-27
HU9302347D0 (en)	1993-10-28
CN1064407A (zh)	1992-09-16
NO932681L (no)	1993-10-07
FI933595A7 (fi)	1993-08-13
MA22443A1 (fr)	1992-10-01
IL100906A0 (en)	1992-11-15
MY131098A (en)	2007-07-31
LTIP329A (en)	1994-08-25
WO1992014454A1 (fr)	1992-09-03
AP9200356A0 (en)	1992-04-30
HUT65634A (en)	1994-07-28
GB9103075D0 (en)	1991-03-27
AP549A (en)	1996-11-01
GB2254554A (en)	1992-10-14
MX9200622A (es)	1992-11-01
ZA921037B (en)	1992-11-25
CA2104009A1 (fr)	1992-08-14
IS3814A (is)	1992-08-14
AU5590696A (en)	1996-08-08
EP0499467A2 (fr)	1992-08-19
IE920464A1 (en)	1992-08-12
BR9205642A (pt)	1994-06-21
IL100906A (en)	1996-09-12
AU1233992A (en)	1992-09-15
GB9203084D0 (en)	1992-03-25
OA09535A (en)	1992-11-15
JPH06505231A (ja)	1994-06-16
EP0499467A3 (en)	1992-12-16
DZ1559A1 (fr)	2002-02-17
CZ166893A3 (en)	1994-03-16

Publication	Publication Date	Title
SK87993A3 (en)	1993-12-08	Pharmaceutical composition
AU2001230977B2 (en)	2006-10-12	Combinations for treating neoplasms
US6537990B1 (en)	2003-03-25	Combined preparations comprising morpholine anthracyclines and anticancer agent
AU2927999A (en)	1999-09-15	Use of epothilones for the treatment of cancer
GB1583661A (en)	1981-01-28	Tumour antidote
SK138597A3 (en)	1998-05-06	A pharmaceutical composition containing n-chlorophenylcarbamates, n-chlorophenylthiocarbamates and n-phosphonoglycine derivatives for inhibiting the growth of cancers and viruses in mammals
CN110664807B (zh)	2021-07-20	一种具有协同抗黑色素瘤功效的药物组合物及其应用
CN106822099A (zh)	2017-06-13	维生素c与苯磺酰胺化合物协同作用的注射用药物组合物
KR20180066780A (ko)	2018-06-19	뇌종양의 예방 또는 치료용 약학 조성물
KR100369890B1 (ko)	2003-05-12	설사예방및치료제
JP2020537689A (ja)	2020-12-24	Ａ−ノル−５αアンドロスタン化合物を含む白血球増多製剤およびその使用
JPH01313433A (ja)	1989-12-18	抗ｈｉｖ剤
JP4781624B2 (ja)	2011-09-28	Ｒａｎｔｅｓ誘導剤
EA011573B1 (ru)	2009-04-28	Препарат, потенцирующий противоопухолевый эффект, противоопухолевый препарат и способ лечения рака
KR20210039414A (ko)	2021-04-09	암의 치료를 위한 병용 요법
KR20020009929A (ko)	2002-02-02	간암 치료 및 예방용 의약 조성물
JPH0667834B2 (ja)	1994-08-31	抗腫瘍剤
KR100421261B1 (ko)	2004-03-09	피토스핑고신 유도체를 유효 성분으로 포함하는 방사선치료 증진제
JPS61129124A (ja)	1986-06-17	抗腫瘍剤
JPH0558892A (ja)	1993-03-09	発癌防止剤
RU2316321C1 (ru)	2008-02-10	Противовирусное средство для системного применения
CN113827604A (zh)	2021-12-24	瑞德西韦在制备治疗肿瘤或抗肿瘤转移药物中的应用
KR20100131457A (ko)	2010-12-15	시티딘 유도체 및 카르보플라틴을 함유하는 항종양제
MXPA99001505A (en)	1999-06-01	Pharmaceutical compositions comprising tyrphostins
HK1068786A (en)	2005-05-06	Combined preparations comprising anthracycline derivatives